BIOMERIEUX (EPA:BIM) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
BIOMERIEUX

BRIEF

published on 11/06/2024 at 09:59, 15 days 2 hours ago

Status of bioMérieux Shares and Voting Rights for October 2024

Voting Rights BioMérieux Actions Financial Regulation October 2024
BRIEF

published on 11/06/2024 at 09:59, 15 days 2 hours ago

État des Actions et Droits de Vote de bioMérieux pour Octobre 2024

Droits De Vote BioMérieux Actions Règlement Financier Octobre 2024
REGULATED PRESS RELEASE

published on 11/06/2024 at 09:54, 15 days 3 hours ago

Octobre 2024 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
bioMérieux informe sur le nombre total de droits de vote et d'actions au 31/10/2024. Les détails sont conformes à la réglementation financière en vigueur

Droits De Vote BioMérieux Actions Règlement Général Informations Mensuelles
BRIEF

published on 10/30/2024 at 07:06, 22 days 5 hours ago

BioMérieux : Croissance organique soutenue au troisième trimestre 2024

BioMérieux Croissance Organique Panels BIOFIRE® SPOTFIRE® GO•28
BRIEF

published on 10/30/2024 at 07:06, 22 days 5 hours ago

BioMérieux Reports Solid Third-Quarter Performance in 2024

Financial Performance Diagnostic Solutions Sales Growth BioMérieux 2024 GO•28 Strategy
REGULATED PRESS RELEASE

published on 10/30/2024 at 07:01, 22 days 5 hours ago

bioMérieux – Third-Quarter 2024 Business Review
bioMérieux reports strong +10.3% organic sales growth, reaching €2,871m in the first nine months of 2024, driven by growth drivers like GO•28 strategic plan and BIOFIRE® respiratory panels. Q3 2024 shows an +11% organic sales growth with confirmation of 2024 full-year revised guidance. CEO Pierre Boulud expresses confidence in achieving targets

BioMérieux Organic Sales Growth 2024 Guidance GO•28 Strategic Plan BIOFIRE Respiratory Panels
REGULATED PRESS RELEASE

published on 10/30/2024 at 07:01, 22 days 5 hours ago

bioMérieux – Information financière du 3ème trimestre 2024
bioMérieux annonce une croissance organique de +10,3% au 3ème trimestre 2024, avec une dynamique forte dans les segments cliniques et industriels, confirmant les objectifs annuels. Le Directeur Général souligne la performance dynamique et l'engagement des collaborateurs

BioMérieux Objectifs Annuels Croissance Organique 3ème Trimestre 2024 Segments Cliniques
BRIEF

published on 10/15/2024 at 07:06, 1 month 6 days ago

BioMérieux Receives CE-Marking for VIDAS® Vitamin B12 Test

BioMérieux Diagnostics Vitamin B12 CE-marking VIDAS®
BRIEF

published on 10/15/2024 at 07:06, 1 month 6 days ago

BioMérieux reçoit le marquage CE pour le test VIDAS® VITAMIN B12 TOTAL

BioMérieux Diagnostic In Vitro Vitamine B12 Test VIDAS® Anémie
REGULATED PRESS RELEASE

published on 10/15/2024 at 07:01, 1 month 6 days ago

bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to measure total Vitamin B12 concentration
bioMerieux announces CE-marking for VIDAS Vitamin B12 Total, an automated blood test to measure total B12 concentration in serum or plasma, aiding in the assessment of B12 status and optimizing patient care

BioMérieux CE-marking VIDAS Vitamin B12 Total Blood Test

Accesswire

Published on 11/21/2024 at 12:00, 57 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 57 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 27 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 54 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 57 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 22 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 42 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 50 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 57 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 27 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 59 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 59 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 59 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 50 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 37 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE